SCHEMBL10116259

SCHEMBL10116259

Cc1cc(C(=O)Nc2ccc3oc(=O)ccc3c2)ccc1NS(=O)(=O)C(C)(C)C

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
ALDH1A1 P00352 7/20 0.49
HPGD P15428 3/20 0.49
HSD17B10 Q99714 2/20 0.49
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 4/20 0.47
TP53 P04637 2/20 0.47
PKM P14618 2/20 0.46
SNCA P37840 1/20 0.46
POLB P06746 1/20 0.46
MAPT P10636 1/20 0.46
GAA P10253 1/20 0.45
PPARG P37231 1/20 0.45
NR2E3 Q9Y5X4 1/20 0.45
NCOR2 Q9Y618 1/20 0.45
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116245 0.87 KMT2A (0.61) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL10116538 0.86 MEN1 (0.57) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL13565351 0.79 MEN1 (0.48) MEN1KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL12707728 0.78 KMT2A (0.80) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL10116527 0.75 MEN1 (0.61) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL10116253 0.74 MAOB (0.40) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL10133523 0.73 THRB (0.48) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL10116255 0.73 THRB (0.48) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL12882048 0.72 MAOB (0.48) RAB9AALDH1A1KDM4ETP53MAPT
SCHEMBL10116261 0.71 MEN1 (0.40) MEN1KMT2ANPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R MEN1 2876/4885KMT2A 2912/4885NPC1 1435/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2932/4885KMT2A 2768/4885NPC1 1353/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R MEN1 2926/4885KMT2A 2953/4885NPC1 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.